|
1
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
et al: SEER cancer statistics review, 1975–2012, National Cancer
Institute. 2013.
|
|
2
|
Demicheli R, Valagussa P and Bonadonna G:
Does surgery modify growth kinetics of breast cancer
micrometastases? Br J Cancer. 85:490–492. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hansen E, Wolff N, Knuechel R, Ruschoff J,
Hofstaedter F and Taeger K: Tumor cells in blood shed from the
surgical field. Arch Surg. 130:387–393. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang J and Wu GS: Role of autophagy in
cisplatin resistance in ovarian cancer cells. J Biol Chem.
289:17163–17173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Walsh V and Goodman J: From taxol to
Taxol: The changing identities and ownership of an anti-cancer
drug. Med Anthropol. 21:307–336. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liebmann JE, Cook JA, Lipschultz C, Teague
D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel
(Taxol) in human tumour cell lines. Br J Cancer. 68:1104–1109.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Manfredi JJ and Horwitz SB: Taxol: An
antimitotic agent with a new mechanism of action. Pharmacol Ther.
25:83–125. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kampan NC, Madondo MT, Mcnally OM, Quinn M
and Plebanski M: Paclitaxel and its evolving role in the management
of ovarian cancer. Biomed Res Int. 2015:4130762015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pritchard JE, Dillon PM, Conaway MR, Silva
CM and Parsons SJ: A mechanistic study of the effect of
doxorubicin/adriamycin on the estrogen response in a breast cancer
model. Oncology. 83:305–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bao L, Haque A, Jackson K, Hazari S, Moroz
K, Jetly R and Dash S: Increased expression of P-glycoprotein is
associated with doxorubicin chemoresistance in the metastatic 4T1
breast cancer model. Am J Pathol. 178:838–852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Siena L, Pace E, Ferraro M, Di Sano C,
Melis M, Profita M, Spatafora M and Gjomarkaj M: Gemcitabine
sensitizes lung cancer cells to Fas/FasL system-mediated killing.
Immunology. 141:242–255. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
García MA, Carrasco E, Aguilera M, Alvarez
P, Rivas C, Campos JM, Prados JC, Calleja MA, Esteban M, Marchal
JA, et al: The chemotherapeutic drug 5-fluorouracil promotes
PKR-mediated apoptosis in a p53-independent manner in colon and
breast cancer cells. PLoS One. 6:e238872011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama
H, Masuda H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, et al:
Effects of chemotherapy and hormonal therapy for early breast
cancer on recurrence and 15-year survival: An overview of the
randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tomar D and Singh R: TRIM family proteins:
Emerging class of RING E3 ligases as regulator of NF-κB pathway.
Biol Cell. 107:22–40. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Shi W, Shi H, Lu S, Kang W, Chao
S, He J, Jin W, Lv X, Zou H and Shu Y: TRIM11 overexpression
promotes proliferation, migration and invasion of lung cancer
cells. J Exp Clin Cancer Res. 35:1002016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin Y, Zhong J, Li SW, Li JZ, Zhou M, Chen
Y, Sang Y and Liu L: TRIM11, a direct target of miR-24-3p, promotes
cell proliferation and inhibits apoptosis in colon cancer.
Oncotarget. 7:86755–86765. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Y, Sun J and Ma J: Proliferation and
invasion of ovarian cancer cells are suppressed by knockdown of
TRIM11. Oncol Lett. 14:2125–2130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chambon M, Orsetti B, Berthe ML,
Bascoul-Mollevi C, Rodriguez C, Duong V, Gleizes M, Thénot S,
Bibeau F, Theillet C and Cavaillès V: Prognostic significance of
TRIM24/TIF-1α gene expression in breast cancer. Am J Pathol.
178:1461–1469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia
W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, et al: TRIM24
links a non-canonical histone signature to breast cancer. Nature.
468:927–932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ai L, Kim WJ, Alpay M, Ming T, Pardo CE,
Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM, et al:
TRIM29 suppresses TWIST1 and invasive breast cancer behavior.
Cancer Res. 74:4875–4887. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong JY, Kang B, Kim A, Hwang S, Ahn J,
Lee S, Kim J, Park JH and Cheon DS: Development of a highly
sensitive real-time one step RT-PCR combined complementary locked
primer technology and conjugated minor groove binder probe. Virol
J. 8:3302011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao G and Dou QP: G1
phase-dependent expression of Βcl-2 mRNA and protein correlates
with chemoresistance of human cancer cells. Mol Pharmacol.
58:1001–1010. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bu Y, Lu C, Bian C, Wang J, Li J, Zhang B,
Li Z, Brewer G and Zhao RC: Knockdown of Dicer in MCF-7 human
breast carcinoma cells results in G1 arrest and increased
sensitivity to cisplatin. Oncol Rep. 21:13–17. 2009.PubMed/NCBI
|
|
28
|
Bhatnagar S, Gazin C, Chamberlain L, Ou J,
Zhu X, Tushir JS, Virbasius CM, Lin L, Zhu LJ, Wajapeyee N and
Green MR: TRIM37 is a new histone H2A ubiquitin ligase and breast
cancer oncoprotein. Nature. 516:116–120. 2014.PubMed/NCBI
|
|
29
|
Li Z, Li X, Wei D, Sun C, Guo D and Zhang
L: Mmu-miR-1894-3p inhibits cell proliferation and migration of
breast cancer cells by targeting Trim46. Int J Mol Sci.
17:E6092016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li J, Yen C, Liaw D, Podsypanina K, Bose
S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al:
PTEN, a putative protein tyrosine phosphatase gene mutated
in human brain, breast, and prostate cancer. Science.
275:1943–1947. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miyashita T, Harigai M, Hanada M and Reed
JC: Identification of a p53-dependent negative response element in
the bcl-2 gene. Cancer Res. 54:3131–3135. 1994.PubMed/NCBI
|
|
32
|
Silvestrini R, Veneroni S, Daidone MG,
Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi
U: The Bcl-2 protein: A prognostic indicator strongly related to
p53 protein in lymph node-negative breast cancer patients. J Natl
Cancer Inst. 86:499–504. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao G, Zhu Y, Eno CO, Liu Y, Deleeuw L,
Burlison JA, Chaires JB, Trent JO and Li C: Activation of the
proapoptotic Bcl-2 protein Bax by a small molecule induces tumor
cell apoptosis. Mol Cell Biol. 34:1198–1207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miyashita T, Krajewski S, Krajewska M,
Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor
suppressor p53 is a regulator of bcl-2 and bax gene expression in
vitro and in vivo. Oncogene. 9:1799–1805. 1994.PubMed/NCBI
|
|
35
|
Miyashita T and Reed JC: Tumor suppressor
p53 is a direct transcriptional activator of the human bax gene.
Cell. 80:293–299. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kohno M and Pouyssegur J: Targeting the
ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin A: Activation of the JNK signaling
pathway: Breaking the brake on apoptosis. Bioessays. 25:17–24.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nunes-Xavier CE, Elson A and Pulido R:
Epidermal growth factor receptor (EGFR)-mediated positive feedback
of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and
AKT protein pathways is required for survival of human breast
cancer cells. J Biol Chem. 287:3433–3444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cellurale C, Girnius N, Jiang F,
Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM and Davis RJ: Role
of JNK in mammary gland development and breast cancer. Cancer Res.
72:472–481. 2012. View Article : Google Scholar : PubMed/NCBI
|
